NCT02964936已完成3 期
A Phase 3, Multicenter, Randomized, 2-Arm, Open-label Study of Intermittent Oral Dosing of ASP1517 for the Treatment of Anemia in Erythropoiesis Stimulating Agent-untreated Chronic Kidney Disease Patients Not on Dialysis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 38
- 主要终点
- Change from baseline in hemoglobin (Hb) response rate
研究概览
简要总结
The objective of this study is to evaluate the efficacy and the safety when ASP1517 is intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis chronic kidney disease patients with anemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who were diagnosed with non-dialysis chronic kidney disease (CKD) and who are considered not to require renal replacement therapy during the study period
- •Mean of the subject's two most recent Hb values before randomization during the Screening Period must be <10.5 g/dL with an absolute difference ≤1.3 g/dL between the two values
- •Either transferrin saturation ≥ 5% or serum ferritin ≥ 30 ng/mL
- •Female subject must either:
- •Be of non-childbearing potential:
- •post-menopausal prior to pre-screening, or
- •documented surgically sterile Or, if of childbearing potential,
- •Agree not to try to become pregnant during the study after informed consent acquisition and for 28 days after the final study drug administration
- •And have a negative urine pregnancy test at pre-screening
- •And, if heterosexually active, agree to consistently use two forms of highly effective birth control (at least one of which must be a barrier method) starting at pre-screening and throughout the study period and for 28 days after the final study drug administration.
- •Female subject must agree not to breastfeed starting at pre-screening and throughout the study period, and for 28 days after the final study drug administration.
- •Female subject must not donate ova starting at pre-screening and throughout the study period, and for 28 days after the final study drug administration.
- •Male subject and their female spouse/partners who are of childbearing potential must be using two forms of highly effective birth control (at least one of which must be a barrier method) starting at pre-screening and continue throughout the study period, and for 12 weeks after the final study drug administration
- •Male subject must not donate sperm starting at pre-screening and throughout the study period, and for 12 weeks after the final study drug administration
排除标准
- •Concurrent retinal neovascular lesion requiring treatment and macular edema requiring treatment
- •Concurrent autoimmune disease with inflammation that could impact erythropoiesis
- •History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent gastroparesis
- •Uncontrolled hypertension
- •Concurrent congestive heart failure (NYHA Class III or higher)
- •History of hospitalization for treatment of stroke, myocardial infarction, or pulmonary embolism within 12 weeks before the pre-screening assessment
- •Positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) antibody at the pre-screening assessment, or positive for human immunodeficiency virus (HIV) in a past test
- •Concurrent other form of anemia than renal anemia
- •Having received treatment with ESA, protein anabolic hormone, testosterone enanthate, or mepitiostane within 6 weeks before the pre-screening assessment
- •Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) or total bilirubin that is greater than the criteria, or previous or concurrent another serious liver disease at pre-screening assessment
- •Previous or current malignant tumor (no recurrence for at least 5 years is eligible.)
- •Having undergone red blood transfusion and/or a surgical procedure considered to promote anemia within 4 weeks before the pre-screening assessment
- •Having undergone a kidney transplantation
- •History of serious drug allergy including anaphylactic shock
- •Having a previous history of treatment with ASP1517
- •Participation in another clinical study or post-marketing clinical study (including that of a medical device) within 12 weeks before informed consent acquisition
研究组 & 干预措施
ASP1517 Low dose group
Experimental
Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
干预措施: roxadustat (Drug)
ASP1517 High dose group
Experimental
Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
干预措施: roxadustat (Drug)
结局指标
主要结局
Change from baseline in hemoglobin (Hb) response rate
时间窗: Baseline and week 24
Hb response is defined as reaching target values for Hb.
次要结局
- Number of hospitalizations(Up to Week 24)
- Duration of hospitalizations(Up to Week 24)
- Change from baseline in the average Hb from Week 18 to Week 24(Baseline and Weeks 18 to 24)
- Proportion of participants who achieve the target Hb level at the average of Week 18 to 24(Weeks 18 to 24)
- Rate of rise in Hb levels (g/dL/week) from week 0 at the earliest date of week 4, time to discontinuation, or time of dose adjustment(Up to Week 4)
- Proportion of measurement points with the target Hb level(Weeks 18 to 24)
- Proportion of participants who achieves the target Hb level at each week(Up to Week 24)
- Quality of life assessed by FACT-An(Up to Week 24)
- Proportion of participants who achieves the lower limit of the target Hb level(Up to Week 24)
- Time to achieve the lower limit of the target Hb level(Up to Week 24)
- Change from baseline in Hb level to each week(Baseline and Up to Week 24)
- Safety assessed by body weight(Up to Week 24)
- Safety assessed by incidence of adverse events(Up to Week 24)
- Number of participants with abnormal Laboratory values and/or adverse events related to treatment(Up to Week 24)
- Quality of life assessed by EQ-5D-5L(Up to Week 24)
- Safety assessed by standard 12-lead electrocardiogram(Up to Week 24)
- Number of participants with abnormal Vital signs and/or adverse events related to treatment(Up to Week 24)
- Plasma concentration of unchanged ASP1517(Up to Week 24)
- Average hematocrit level(Up to Week 24)
- Average reticulocyte level(Up to Week 24)
- Average iron (Fe) level(Up to Week 24)
- Average ferritin level(Up to Week 24)
- Average transferrin level(Up to Week 24)
- Average total iron binding capacity level(Up to Week 24)
- Average soluble transferrin receptor level(Up to Week 24)
- Average transferrin saturation level(Up to Week 24)
- Average reticulocyte hemoglobin content level(Up to Week 24)
研究者
研究点 (38)
Loading locations...
相似试验
已完成
3 期
A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With AnemiaChronic Kidney DiseaseNCT02988973Astellas Pharma Inc334
已完成
3 期
A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With AnemiaHemodialysis Chronic Kidney Disease Patients With AnemiaNCT02952092Astellas Pharma Inc303
已完成
1 期
Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male VolunteersHealthy VolunteersNCT00978198Astellas Pharma Inc100
已完成
2 期
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis StudyArthritis, RheumatoidNCT01711814Astellas Pharma Global Development, Inc.611
已完成
3 期
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationLeukemia, Acute Myeloid (AML)NCT02421939Astellas Pharma Global Development, Inc.371